MX2022007130A - Derivados de piperazina sustituidos utiles como activadores de celulas t. - Google Patents
Derivados de piperazina sustituidos utiles como activadores de celulas t.Info
- Publication number
- MX2022007130A MX2022007130A MX2022007130A MX2022007130A MX2022007130A MX 2022007130 A MX2022007130 A MX 2022007130A MX 2022007130 A MX2022007130 A MX 2022007130A MX 2022007130 A MX2022007130 A MX 2022007130A MX 2022007130 A MX2022007130 A MX 2022007130A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- compounds
- derivatives useful
- piperazine derivatives
- substituted piperazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Se describen compuestos de la Fórmula (I): (ver Fórmula) (I) o una sal de los mismos, en donde: R1, R2, R4, R5, R6 y m se definen aquí. También se describen métodos para usar los compuestos para inhibir la actividad de una o ambas diacilglicerol cinasa alfa (DGKa) y diacilglicerol cinasa zeta (DGK?), y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles en el tratamiento de infecciones virales y trastornos proliferativos, tal como el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201911053559 | 2019-12-23 | ||
PCT/US2020/066504 WO2021133749A1 (en) | 2019-12-23 | 2020-12-22 | Substituted piperazine derivatives useful as t cell activators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007130A true MX2022007130A (es) | 2022-07-11 |
Family
ID=74191942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007130A MX2022007130A (es) | 2019-12-23 | 2020-12-22 | Derivados de piperazina sustituidos utiles como activadores de celulas t. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230118629A1 (es) |
EP (1) | EP4081522A1 (es) |
JP (1) | JP2023508375A (es) |
KR (1) | KR20220120624A (es) |
CN (1) | CN115175907A (es) |
AU (1) | AU2020412698A1 (es) |
BR (1) | BR112022012222A2 (es) |
CA (1) | CA3162979A1 (es) |
IL (1) | IL294270A (es) |
MX (1) | MX2022007130A (es) |
WO (1) | WO2021133749A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
WO2023122772A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
CN114437127B (zh) * | 2022-01-28 | 2023-12-22 | 万华节能科技(烟台)有限公司 | 一种基于氧化膦衍生物改性异氰酸酯化合物及其合成方法 |
WO2023150186A1 (en) * | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
WO2023184327A1 (en) * | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
AU2006244068B9 (en) | 2005-05-10 | 2012-10-25 | Incyte Holdings Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
SI2376535T1 (sl) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t |
LT3023438T (lt) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antikūnai |
US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
ME03447B (me) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba |
BR112012022046A2 (pt) | 2010-03-05 | 2017-02-14 | F Hoffamann-La Roche Ag | ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''. |
CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
US8206715B2 (en) | 2010-05-04 | 2012-06-26 | Five Prime Therapeutics, Inc. | Antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
KR101527300B1 (ko) | 2010-09-09 | 2015-06-09 | 화이자 인코포레이티드 | 4-1bb 결합 분자 |
NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
LT2699264T (lt) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1 |
KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
CN104159921B (zh) | 2011-12-15 | 2018-05-04 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
AU2013308635A1 (en) | 2012-08-31 | 2015-03-12 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
MA41168A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
EA202190137A1 (ru) * | 2018-06-27 | 2021-05-17 | Бристол-Маерс Сквибб Компани | Нафтиридиноновые соединения для применения в качестве активаторов t-клеток |
LT3814348T (lt) * | 2018-06-27 | 2023-10-10 | Bristol-Myers Squibb Company | Pakeistieji naftiridinono junginiai, naudotini kaip t ląstelių aktyvatoriai |
-
2020
- 2020-12-22 MX MX2022007130A patent/MX2022007130A/es unknown
- 2020-12-22 EP EP20842856.5A patent/EP4081522A1/en active Pending
- 2020-12-22 WO PCT/US2020/066504 patent/WO2021133749A1/en unknown
- 2020-12-22 KR KR1020227025313A patent/KR20220120624A/ko unknown
- 2020-12-22 AU AU2020412698A patent/AU2020412698A1/en active Pending
- 2020-12-22 US US17/785,749 patent/US20230118629A1/en active Pending
- 2020-12-22 IL IL294270A patent/IL294270A/en unknown
- 2020-12-22 CN CN202080097016.2A patent/CN115175907A/zh active Pending
- 2020-12-22 BR BR112022012222A patent/BR112022012222A2/pt unknown
- 2020-12-22 JP JP2022538860A patent/JP2023508375A/ja active Pending
- 2020-12-22 CA CA3162979A patent/CA3162979A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL294270A (en) | 2022-08-01 |
KR20220120624A (ko) | 2022-08-30 |
AU2020412698A1 (en) | 2022-08-18 |
BR112022012222A2 (pt) | 2022-09-13 |
EP4081522A1 (en) | 2022-11-02 |
US20230118629A1 (en) | 2023-04-20 |
CN115175907A (zh) | 2022-10-11 |
CA3162979A1 (en) | 2021-07-01 |
JP2023508375A (ja) | 2023-03-02 |
WO2021133749A1 (en) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
MX2020013373A (es) | Compuestos de naftiridinona utiles como activadores de celulas t. | |
MX2022007130A (es) | Derivados de piperazina sustituidos utiles como activadores de celulas t. | |
MX2022007372A (es) | Compuestos de heteroarilo sustituidos utiles como activadores de celulas t. | |
MX2022006958A (es) | Compuestos de quinazolinilo sustituidos utiles como activadores de celulas t. | |
MX2022007369A (es) | Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t. | |
ZA202203515B (en) | Substituted pyridopyrimidinonyl compounds useful as t cell activators | |
MX2022007842A (es) | Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t. | |
MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
MX2022005053A (es) | Inhibidores de peque?as moleculas de mutante g12c de kras. | |
PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
EP4104837A3 (en) | Heterocyclic compounds as ret kinase inhibitors | |
AU2011297889A8 (en) | Pharmaceutically active compounds as Axl inhibitors | |
CR20230310A (es) | Inhibidores de prmt5 | |
TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
WO2008132138A9 (en) | AMINOPYRIMIDINE DERIVATIVES DISUBSTITUTED IN 4 AND 6 | |
PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
MX2019006843A (es) | Inhibidor de cdk4/6. | |
MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
AU2020231934A8 (en) | Compounds useful in HIV therapy | |
MX2021009659A (es) | Hidroxipiridoxazepinas como activadores de nrf2. | |
MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. |